secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001558370-25-002750
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 5.03, 3.02, 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood converts $19.9M debt and interest to Series A-1 preferred equity
------------------------------------------------------------------------

- $19.5M principal plus accrued interest ($19,926,891 total) exchanged for 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock.
- Each preferred share convertible into 10,000 common shares, pending stockholder approval and Nasdaq rules.
- All existing debt removed from balance sheet; company funded through Q4 2025 interim of Phase 2b CINP trial.
- Largest shareholder CK Life Sciences (through Conjoint) facilitated the conversion, signaling confidence in Halneuron program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025002750/0001558370-25-002750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025002750/dwtx-20250312x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer